Mayumi Tamaki
Overview
Explore the profile of Mayumi Tamaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
29
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karasawa R, Yudoh K, Sato T, Tanaka M, Tamaki M, Sabbagh S, et al.
Rheumatology (Oxford)
. 2021 Nov;
61(7):2969-2977.
PMID: 34791087
Objectives: JDM is an inflammatory myopathy characterized by prominent vasculopathy. AECAs are frequently detected in inflammatory and autoimmune diseases. We sought to determine whether AECAs correlate with clinical features of...
2.
Karasawa R, Tamaki M, Sato T, Tanaka M, Nawa M, Yudoh K, et al.
Rheumatology (Oxford)
. 2018 Jan;
57(4):671-676.
PMID: 29361142
Objective: Although generally classified within the group of inflammatory myopathies, JDM displays many pathological features of vasculitis. Previous work has shown that AECA are abundant in other forms of vasculitis....
3.
Yamashita A, Tamaki M, Kasai H, Tanaka T, Otoguro T, Ryo A, et al.
Antiviral Res
. 2017 Aug;
145:136-145.
PMID: 28827084
The currently available antiviral agents for chronic infection with hepatitis B virus (HBV) are pegylated interferon-α and nucleoside/nucleotide analogues, although it has been difficult to completely eliminate covalently closed circular...
4.
Yamashita A, Fujimoto Y, Tamaki M, Setiawan A, Tanaka T, Okuyama-Dobashi K, et al.
Mar Drugs
. 2015 Nov;
13(11):6759-73.
PMID: 26561821
The current treatments of chronic hepatitis B (CHB) face a limited choice of vaccine, antibody and antiviral agents. The development of additional antiviral agents is still needed for improvement of...